Fig. 1
From: Paradoxical effect of dopamine-agonists on IGF-1 in patients with prolactinoma: the role of weight
IGF-1, expressed as median at different time points in the whole cohort (a), normal-weight (b) and overweight and obese (c) patients. Friedman Test was used to compare the repeated measurements of IGF-1 over time upon cabergoline therapy. A p < 0.05 was considered significant